Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotinib and chemotherapy in EGFR-mutant lung cancer with gradual progression
NCT03544814Phase 2Completed
- Sponsor
- Shanghai Chest Hospital
- Start
- Jan 2015
- Primary completion
- Jun 2017
- Modality
- Orthosteric Ligands
01
Overview
A Phase 2 trial of icotinib in lung adenocarcinoma, sponsored by Shanghai Chest Hospital. Started Jan 2015; status: completed.
02
Drugs
icotinib
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT03544814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03544814.